STAT+: 7 children developed blood cancer after Bluebird Bio gene therapy for rare neurological disease
STAT
OCTOBER 9, 2024
Newly published data show that seven out of 67 children who received Bluebird Bio’s gene therapy for a devastating neurological disorder in clinical trials have since gone on to develop blood cancers. That means four additional patients have developed blood cancers since June 2022, when concerns about three cancer cases prompted the Food and Drug Administration to hold a hearing of outside advisers before approving the treatment, marketed as Skysona.
Let's personalize your content